Federal Register #FDA2026D7957

FDA Draft Guidance on Container Closure Systems for Human Drugs and Biological Products

The Food and Drug Administration (FDA), under the Department of Health and Human Services, has released a draft guidance for industry regarding container closure systems (CCSs) for human drugs and biological products. - Government Buyer: - Food and Drug Administration (FDA) - Department of Health and Human Services - Purpose: - Draft guidance for evaluating the quality of container closure systems (CCSs) used in packaging human drugs and biological products - Includes CCSs that are device constituent parts of combination products - Key Topics: - Principles for risk-based evaluation frameworks - Quality assessments and quality control of packaging materials and components - Notable Requirements: - No specific products, part numbers, or quantities are requested - No OEMs or vendors are mentioned - The guidance is open for public comment to inform industry practices and regulatory submissions - Procurement Relevance: - This is not a procurement opportunity; no products or services are being solicited

Description

The Food and Drug Administration (FDA) has announced the availability of a draft guidance titled "Container Closure Systems for Human Drugs and Biological Products." This guidance provides principles for evaluating the quality of container closure systems (CCSs) used to package drugs and biological products for human use, including those that are device parts of combination products. The guidance discusses FDA's current thinking on evaluating CCSs according to a risk-based framework that includes quality assessments and quality control of packaging materials and components. Comments on the draft guidance are requested by October 13, 2026, to ensure consideration before finalization.

View original listing